Wagner Syndrome

Wagner syndrome is a rare, inherited eye disorder that causes progressive vision problems. It primarily affects the vitreous—the clear, gel-like substance that fills the inside of the eye—and the retina, the light-sensitive tissue at the back of the eye. In people with Wagner syndrome, the vitreous gel breaks down and becomes watery prematurely, leading to an "empty" appearance inside the eye and the formation of thin, web-like strands. The condition usually begins in childhood or early adolescence. Common early signs include nearsightedness (myopia) and difficulty seeing in the dark (night blindness). As patients get older, they often develop cataracts (clouding of the eye's lens) at a younger age than usual. A major concern with Wagner syndrome is a high risk of retinal detachment, where the retina pulls away from the back of the eye, which can cause severe vision loss if not treated promptly. Wagner syndrome is caused by a genetic mutation passed down from a parent, though it only affects the eyes and does not cause health problems in other parts of the body. While there is no cure, regular and thorough eye exams are crucial. Treatments such as glasses, cataract surgery, and surgical repair of retinal detachments can help manage the symptoms and preserve vision for as long as possible.

Condition category: Vitreoretinal Disorder

Prevalence: Rare, exact prevalence unknown

Inheritance patterns: Autosomal Dominant

Age of onset: Typically begins in childhood or early adolescence, with signs of vitreous degeneration seen as early as age two years.

Clinical overview: Wagner syndrome, also known as Wagner vitreoretinopathy (WGVRP), is a rare, autosomal dominant hereditary vitreoretinal degeneration. First described by Hans Wagner in 1938 in a large Swiss pedigree, the condition is characterized by an "optically empty" vitreous cavity, avascular vitreous strands and veils, mild to moderate myopia, presenile cataracts, and progressive chorioretinal atrophy. Unlike some other vitreoretinopathies, Wagner syndrome is strictly an ocular disorder and does not present with systemic extraocular manifestations. The clinical significance of Wagner syndrome lies in its progressive nature and the high risk of severe visual impairment. Patients frequently develop early-onset cataracts and are at a significantly increased risk for retinal detachment, which can be either rhegmatogenous or tractional. The progressive chorioretinal atrophy also leads to night blindness (nyctalopia) and visual field constriction. Wagner syndrome is genetically linked to mutations in the VCAN gene (OMIM 118661), which encodes the proteoglycan versican. The condition is classified under OMIM 143200 and Orphanet 898. It shares phenotypic similarities with other vitreoretinopathies, such as Stickler syndrome, but is distinguished by its specific genetic etiology and the absence of systemic features. Erosive vitreoretinopathy (ERVR) is now considered an allelic variant of Wagner syndrome.

Patient and family guide: Wagner syndrome is a rare, inherited eye disorder that causes progressive vision problems. It primarily affects the vitreous—the clear, gel-like substance that fills the inside of the eye—and the retina, the light-sensitive tissue at the back of the eye. In people with Wagner syndrome, the vitreous gel breaks down and becomes watery prematurely, leading to an "empty" appearance inside the eye and the formation of thin, web-like strands. The condition usually begins in childhood or early adolescence. Common early signs include nearsightedness (myopia) and difficulty seeing in the dark (night blindness). As patients get older, they often develop cataracts (clouding of the eye's lens) at a younger age than usual. A major concern with Wagner syndrome is a high risk of retinal detachment, where the retina pulls away from the back of the eye, which can cause severe vision loss if not treated promptly. Wagner syndrome is caused by a genetic mutation passed down from a parent, though it only affects the eyes and does not cause health problems in other parts of the body. While there is no cure, regular and thorough eye exams are crucial. Treatments such as glasses, cataract surgery, and surgical repair of retinal detachments can help manage the symptoms and preserve vision for as long as possible.

Symptoms and clinical features: In the early stages of Wagner syndrome, typically presenting in childhood or early adolescence, patients may be asymptomatic or experience mild visual disturbances. The earliest clinical signs are often observed on examination, including an optically empty vitreous cavity with avascular fibrillary condensations or veils. Mild to moderate myopia is common, and patients may begin to notice difficulty with dark adaptation, leading to early symptoms of night blindness (nyctalopia). During the intermediate stages, usually in young adulthood to middle age, the symptoms become more pronounced. Night blindness worsens, and patients may experience peripheral visual field constriction due to progressive chorioretinal atrophy. Presenile cataracts frequently develop during this stage, causing a gradual decline in central visual acuity, glare, and hazy vision. Patients are also at a high risk of experiencing symptoms related to retinal tears or detachment, such as sudden onset of floaters, photopsia (flashes of light), or a curtain-like shadow over their vision. In the advanced stages, typically occurring in older adulthood, severe visual impairment is common. The chorioretinal atrophy becomes extensive, often involving the posterior pole and macula, leading to significant loss of central and peripheral vision. Complications from recurrent or complex retinal detachments, including tractional detachments, can result in profound vision loss. Advanced cataracts, if left untreated, further obscure vision. In some cases, patients may progress to bilateral blindness.

Molecular pathology: Wagner syndrome is caused by mutations in the VCAN gene, which encodes versican, a large extracellular matrix proteoglycan. Versican is widely expressed in human tissues and plays a crucial structural role in the vitreous humor of the eye. It interconnects various components of the extracellular matrix, including hyaluronan and collagen fibrils, through its terminal domains. Under normal physiological conditions, the glycosaminoglycan regions of versican are thought to prevent collagen fibrils from adhering to one another, thereby maintaining the gel-like consistency and optical clarity of the vitreous. The VCAN gene undergoes alternative splicing to produce different isoforms (V0, V1, V2, and V3), which vary in their glycosaminoglycan attachment domains. In Wagner syndrome, mutations specifically affect the splice acceptor or donor sites of introns 7 and 8 of the VCAN gene. These mutations disrupt normal splicing, leading to the production of aberrant versican isoforms or an imbalance in the normal isoform ratio. This results in a significant reduction of glycosaminoglycans in the vitreous extracellular matrix. The loss of these negatively charged, water-binding molecules leads to the premature liquefaction (syneresis) of the vitreous gel, the formation of avascular vitreous strands, and the characteristic "optically empty" vitreous cavity observed in patients. The altered vitreoretinal interface also predisposes to abnormal tractional forces on the retina.

Genetics: Wagner syndrome is inherited in an autosomal dominant pattern with complete penetrance, meaning all individuals who inherit the mutated gene will develop the condition to some degree, although clinical expressivity can vary significantly even within the same family. De novo mutations have also been reported, though most patients have an affected parent. The condition is caused by heterozygous mutations in the VCAN gene (also known as CSPG2), located on chromosome 5q13-q14. VCAN encodes the extracellular matrix proteoglycan versican. All known pathogenic mutations resulting in Wagner syndrome occur at the splice acceptor or splice donor sites of introns 7 and 8 of the VCAN gene. These splice site mutations lead to alternative splicing events that alter the glycosaminoglycan attachment sites and other extracellular matrix-binding regions of the versican protein. This results in aberrant forms of versican with reduced glycosaminoglycan content, which is thought to cause premature liquefaction of the vitreous gel and subsequent vitreoretinal degeneration. Erosive vitreoretinopathy (ERVR) is considered an allelic disorder caused by mutations in the same gene.

Diagnostic evaluation: Diagnosis of Wagner syndrome is primarily based on clinical findings and family history, confirmed by genetic testing. The hallmark finding on slit-lamp examination is an optically empty vitreous cavity with avascular vitreous strands and veils. Fundoscopy typically reveals progressive chorioretinal atrophy, pigmentary changes, and occasionally ectopic fovea or pseudoexotropia. Retinal traction and detachment are common complications that require careful monitoring. Optical coherence tomography (OCT) demonstrates significant thinning of nearly all retinal layers consistent with chorioretinal atrophy. It may also reveal multilayered membranes of high reflectivity at the vitreoretinal surface, which tend to stay attached to the perifoveal region, creating a bridge over the fovea. OCT angiography can show perivascular loss of the superficial retinal capillary plexus. Full-field electroretinography (ERG) typically shows attenuated a-wave and b-wave amplitudes, affecting both rod and cone systems, which correlates with the severity of chorioretinal pathology. Genetic testing for mutations in the VCAN gene is the definitive diagnostic method. Sequence analysis of the splice acceptor and donor sites of introns 7 and 8 is recommended as a first step, as all known pathogenic mutations associated with Wagner syndrome have been found in these regions. The differential diagnosis includes Stickler syndrome, erosive vitreoretinopathy (ERVR), and other inherited vitreoretinopathies. Unlike Stickler syndrome, Wagner syndrome does not present with systemic extraocular manifestations such as hearing loss or skeletal abnormalities.

Differential diagnosis: Differential diagnosis of Wagner syndrome includes: (1) Stickler syndrome — similar vitreoretinal findings but with systemic features (arthropathy, hearing loss, midface hypoplasia); COL2A1/COL11A1 mutations. (2) Jansen syndrome (erosive vitreoretinopathy) — similar vitreous changes, may be allelic. (3) Snowflake vitreoretinal degeneration — crystalline deposits, fibrillar vitreous degeneration. (4) Familial exudative vitreoretinopathy — peripheral avascularity, exudation. (5) Marfan syndrome — lens subluxation, tall stature, aortic root dilation.

Natural history: The natural history of Wagner syndrome is characterized by progressive vitreoretinal degeneration. The initial signs, such as an optically empty vitreous and avascular veils, typically manifest in childhood or early adolescence, sometimes as early as two years of age. Mild myopia and night blindness often develop early in the disease course. As patients age, the condition progresses with increasing chorioretinal atrophy, pigmentary changes, and the development of presenile cataracts, which often require surgical extraction by the third or fourth decade of life. The risk of retinal detachment, both rhegmatogenous and tractional, is significantly elevated and can occur at any age, though it frequently presents in young adulthood. Visual acuity may remain relatively preserved in the early stages but tends to decline progressively due to cataracts, chorioretinal atrophy, or complications from retinal detachment. By the fifth decade and beyond, patients often experience severe visual impairment, and bilateral blindness can occur in advanced cases. The severity and rate of progression can vary widely among affected individuals, even within the same family.

Management and treatment research: ### Current management and monitoring There is no cure or treatment that corrects the underlying genetic cause of Wagner syndrome. Care focuses on monitoring the retina and vitreous closely, treating complications promptly, and supporting vision and daily activities. Wagner syndrome is most often caused by disease-causing variants in the *VCAN* gene and is usually inherited in an autosomal dominant pattern. Regular follow-up with an ophthalmologist experienced in vitreoretinal and inherited retinal conditions is important. The timing of visits should be individualized based on retinal findings, symptoms, and previous eye procedures. Management may include: - **Correction of refractive errors:** Glasses or contact lenses may improve myopia (nearsightedness) or other focusing problems. - **Retinal monitoring:** Dilated eye examinations and retinal imaging help detect retinal tears, retinal detachment, and progressive retinal changes. - **Urgent assessment of new symptoms:** Flashes of light, a sudden increase in floaters, a curtain or shadow in vision, or sudden vision loss may indicate a retinal tear or detachment and require urgent eye care. - **Cataract care:** Cataracts that interfere with vision or daily activities may be treated with standard cataract surgery. Retinal and vitreous changes associated with Wagner syndrome should be considered when planning surgery. - **Treatment of retinal tears or detachment:** Retinal tears may be treated with laser retinopexy or cryotherapy (freezing treatment) to reduce the risk of detachment. Retinal detachment generally requires surgery, which may include vitrectomy (removal of vitreous gel) and/or scleral buckling. Surgery can be more complex because of abnormal vitreous and retinal attachments. - **Low-vision support:** Low-vision evaluations, magnifiers, improved lighting, orientation strategies, and assistive technology can help maintain independence when vision is reduced. Genetic counseling can help affected individuals and families understand genetic testing, autosomal dominant inheritance, and the chance of passing a *VCAN* variant to children. ### Approved therapies There are currently **no approved medicines, gene therapies, or other treatments that address the underlying cause of Wagner syndrome**. Available treatment is directed toward eye complications and visual rehabilitation. ### Investigational therapies and research There are currently no Wagner syndrome-specific treatments in the reported clinical development pipeline. Research continues to examine how changes in *VCAN* affect versican, a protein important to the vitreous—the gel-like material inside the eye—and the retina. This work may improve understanding of disease progression and help inform future treatment approaches. Gene replacement, gene editing, and other molecular treatments are not established therapies for Wagner syndrome at this time. ### Clinical trial participation No interventional clinical trials for Wagner syndrome were identified in the current trial data. Trials with the word “Wagner” in a listed name or investigator information are not necessarily related to Wagner syndrome; the current listings concern unrelated conditions. People interested in research participation may ask a vitreoretinal specialist, inherited retinal disease clinic, or genetic counselor about registries, genetic studies, or natural-history studies. These studies can help researchers better understand Wagner syndrome and support future clinical research.

Outlook: The prognosis for visual outcomes in Wagner syndrome is highly variable, ranging from mild visual impairment to complete bilateral blindness. Visual acuity is often well-maintained in childhood and early adulthood, provided that refractive errors are corrected and retinal detachments are promptly treated. However, progressive chorioretinal atrophy and the development of presenile cataracts typically lead to a gradual decline in vision as patients age. Quality of life can be significantly impacted by the progressive nature of the disease, the need for multiple ocular surgeries (such as cataract extraction and retinal detachment repair), and the psychological burden of living with a chronic, vision-threatening condition. Early diagnosis, regular monitoring by a vitreoretinal specialist, and timely surgical intervention for complications are critical factors in optimizing long-term visual outcomes and maintaining independence.

Epidemiology: Wagner syndrome is an extremely rare genetic disorder with an estimated prevalence of less than 1 in 1,000,000 individuals. The exact prevalence remains unknown due to its rarity and potential underdiagnosis. To date, approximately 300 affected individuals have been described in the medical literature worldwide. The condition does not appear to have a specific ethnic predilection, having been reported in families of European, Asian, African-American, and Caucasian-American descent. About half of the reported cases originate from the Netherlands, where a founder effect has been identified.

Selected references: 1. Wagner H. Ein bisher unbekanntes Erbleiden des Auges (Degeneratio hyaloideo-retinalis hereditaria), beobachtet im Kanton Zuerich. Klin Monatsbl Augenheilkd. 1938;100:840-857. 2. Kloeckener-Gruissem B, Bartholdi D, Abdou MT, Zimmermann DR, Berger W. Identification of the genetic mutation in the original Wagner syndrome family. Mol Vis. 2006;12:350-355. PMID: 16636652 3. Miyamoto T, Inoue AW, Sakamoto Y, et al. Identification of a novel splice site mutation of the CSPG2 gene in a Japanese family with Wagner syndrome. Invest Ophthalmol Vis Sci. 2005;46(8):2726-2735. PMID: 16043841 4. Mukhopadhyay A, Nikopoulos K, Maugeri A, et al. Erosive vitreoretinopathy and wagner disease are caused by heterozygous mutations in the VCAN gene. Am J Hum Genet. 2006;79(4):720-725. PMID: 16960809 5. Zech JC, Morle L, Vincent P, et al. Wagner vitreoretinal degeneration with chromosome 5q31.1 linkage in a French family. Ophthalmic Genet. 1999;20(2):71-80. PMID: 10420194 6. Graemiger RA, Niemeyer G, Schneeberger SA, Messmer EP. Wagner macaque's syndrome: a follow-up study of the original pedigree. Ophthalmology. 1995;102(12):1830-1839. PMID: 9098285 7. Brezin AP, Nedelec B, Barriol R, et al. A new VCAN/CSPG2 mutation causes Wagner syndrome associated with erosive vitreoretinopathy. Invest Ophthalmol Vis Sci. 2011;52(10):7379-7384. PMID: 21849423 8. Szeligowski T, Cehajic-Kapetanovic J, Raji S, et al. Multimodal Evaluation and Management of Wagner Syndrome-Three Patients from an Affected Family. Genes (Basel). 2024;15(9):1178. PMID: 39336769